APGE Stock Price, Analysis & Fundamentals | Apogee Therapeutics, Inc.

Analysis

Apogee Therapeutics, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $5.30 billion. It operates on a large scale, employing 196 people. The company's industry classification aligns it with other companies developing innovative treatments and therapies. Financially, Apogee Therapeutics has reported significant losses, with net income of -$253,674,000 over the trailing twelve months (TTM). Additionally, its EBITDA was -$282,332,000, and free cash flow stood at -$143,327,504. The company's margins are heavily negative across all categories: gross margin, operating margin, and profit margin were each 0.0%. Its returns on equity and assets were also negative at -38.4% and -25.3%, respectively. Apogee Therapeutics has a modest amount of debt ($9.85M) compared to its cash balance ($527.29M), resulting in a debt-to-equity ratio of 1.68. Apogee Therapeutics' valuation metrics are notable for their negative P/E and EV/EBITDA ratios (-15.60 and -16.28, respectively). The company's price-to-book ratio is 7.84. The absence of dividend information prevents further discussion on this topic.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Visit website →

APGE

Price History (1Y)

Analysis

About Apogee Therapeutics, Inc.

Key Statistics

Company Info